HypertrophySalmonNCT03870165
Food First Approach to Stimulate Muscle Protein Synthesis in Healthy Adults
A study testing Resistance exercise, Salmon and Isolated amino acids and fatty acids in people with Hypertrophy, run by University of Illinois at Urbana-Champaign at 1 site in United States.
Trial summary
In a crossover design 10 young healthy adults (20-35 y) will receive stable isotope tracer infusions and perform a single bout of resistance exercise. Immediately after exercise participants will ingest either 3.5 oz of Salmon fillet or its constituent macronutrients as isolated amino acids and fat. Read more about this study
- Who is it for?
- Ages 20 to 35 yearsHealthy volunteers can take part
- Conditions the study is for
- Hypertrophy
- What is being tested?
- Resistance exercise, Salmon and Isolated amino acids and fatty acids
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 10 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Mar 2019to 22 Nov 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 35 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Age 20-35 years
- Recreationally-active adults: ≥ 30 min of physical activity at moderate intensity ≥ 3 times per week
- English fluency
Who cannot join
- Smoking
- Known allergies to fish consumption
- Vegans
- Diagnosed GI tract diseases
- Arthritic conditions
- A history of neuromuscular problems
Show all 20Show fewer
- Diagnosed cognitive impairments
- Recent (1 year) participation in amino acid tracer studies
- Predisposition to hypertrophic scarring or keloid formation
- Individuals on any medications known to affect protein metabolism (i.e. corticosteroids, non-steroidal anti-inflammatories, or prescription strength acne medications).
- High blood pressure (Systolic > 140 mm HG; Diastolic > 90 mm HG)
- Alcohol consumption >10 drinks per week
- Metabolic disorders (e.g., Metabolic Syndrome, diabetes, thyroid diseases)
- Consumption of thyroid, androgenic or other medications known to affect endocrine function
- Consumption of ergogenic-leves of dietary supplements that may affect muscle mass (e.g., creatine, HMB), insulin-like substances, or anabolic/catabolic pro-hormones (e.g., DHEA) within 6 weeks prior to participation
- Currently pregnant
- A suboptimal diet quality score as assessed by ASA24 dietary records
- Asthma
- Hypogonadism
- Cardiovascular disease, arrhythmias
Trial locations and contacts
1 site in 1 country.
About this study
In a crossover design 10 young healthy adults (20-35 y) will receive stable isotope tracer infusions and perform a single bout of resistance exercise. Immediately after exercise participants will ingest either 3.5 oz of Salmon fillet or its constituent macronutrients as isolated amino acids and fat. Repeated blood and breath samples as well as muscle biopsies will be collected to determine whole body amino acid kinetics, muscle amino acid transporters, anabolic signalling and myofibrillar protein synthesis rates during the trials
Read the detailed description
On both infusion trials, participants will report to the laboratory at 0700 h after an overnight fast. Upon arrival to the lab, the participant will fill out a questionnaire and a baseline breath sample will be collected to determine 13CO2 enrichment by isotope ratio mass spectrometry. A Teflon catheter will be inserted into the antecubital vein for a baseline blood sample (t=-210) and then participants will receive priming doses of NaH13CO2 (2.35 µmol·kg-1), L-[1-13C]leucine (7.6 µmol·kg-1), and L-[ring-2H5]phenylalanine (2.0 µmol·kg-1). Subsequently, a continuous intravenous solution of L-[1-13C]leucine (0.10 µmol·kg-1·min-1) and L-[ring-2H5]phenylalanine (0.05 µmol·kg-1·min-1) will be initiated (t=-210) and maintained over the infusion trials. A second Teflon catheter will be inserted into a heated dorsal vein for repeated arterialized blood sampling and remained patent by a 0.9% saline drip. Breath samples and arterialized blood samples will be collected every 30 to 60 minutes during the postabsorptive and postprandial states. In the post-absorptive state of infusion trial 1, muscle biopsies will be collected at t=-150 and -30 min of infusion to determine basal-state myofibrillar protein synthesis rates, relative skeletal muscle amino acid transporter content, and anabolic-related signaling. In the subsequent cross-over trial only 1 muscle biopsy will be collected at t=-30 for Western blot analysis and postabsorptive myofibrillar protein-bound tracer enrichment. After collection of the resting muscle biopsy at t=-30 for both trials, the participants will perform resistance exercise that consists of 4 sets of 10-12 repetitions or to muscular failure at 65-70% of 1-RM for both leg press and leg extension exercise.
Immediately after the completion of the exercise bout, participants will ingest either 3.5 oz of Salmon fillet or a matched isolated amino acid and fat mixture (t=0). Completion of the meal will mark the start of the postprandial stage and additional muscle biopsies will be collected at t=120 and t=300.
- Conditions
- Hypertrophy
- Being tested
- Resistance exercise, Salmon, Isolated amino acids and fatty acids
- Medical subject headings
- Hypertrophy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Resistance exerciseBehavioural
Participants will perform leg press and leg extension immediately prior to ingestion of salmon or isolated mixture
SalmonOther
Participants will ingest salmon immediately after resistance exercise
Isolated amino acids and fatty acidsDietary supplement
Participants will ingest a mixture of isolated amino acids and fatty acids immediately after resistance exercise
| Study group | Role | What they receive |
|---|---|---|
| Salmon | Active comparator | After resistance exercise, participants will ingest 3.5 oz of salmon fillet (21g protein, 24g fat) cooked sous-vide. Receives: Behavioral: Resistance exercise; Other: Salmon |
| Isolated mixture | Experimental | After resistance exercise, participants will ingest an isolated amino acid and fatty acid mixture matched to the amino acid and fatty acid content of 3.5 oz salmon fillet. Receives: Behavioral: Resistance exercise; Dietary Supplement: Isolated amino acids and fatty acids |
What is being measured
The primary outcome is the main question the study is designed to answer.
Fractional synthetic rate of myofibrillar proteins
Myofibrillar protein synthesis rates will be assessed during the postabsorptive period for 3 hr and during the 5 hr after the ingestion of the experimental interventions. This will allow us to assess the change from the postabsorptive to the postprandial period.
Measured: Postabsorptive for 3 hours, postprandial for 5 hours.
Secondary outcomes (2)
Phosphorylation of muscle anabolic signaling
Phosphorylation of anabolic signaling pathways will be assessed in the fasted state and at 2 and 5 hr after the ingestion of the experimental interventions.
Measured: Baseline and at 2 and 5 hours after protein ingestion
Exogenous rate of leucine appearance
Leucine oxidation rates will be assessed in the fasted state and at multiple time points in the postprandial phase.
Measured: 5 hour postprandial phase
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Mar 2019
- Study start1 Mar 2019
- Primary completion22 Nov 2019
- Study completion22 Nov 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for HypertrophyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 10 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Illinois at Urbana-Champaign
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Nicholas Burd, University of Illinois at Urbana-Champaign
- Investigators
- Nicholas A Burd, PhD, Principal investigator, University of Illinois at Urbana-Champaign
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03870165
- Sponsor's protocol ID
- 19293
- Acronym
- Salmon
- Status last verified
- Sep 2020
- First submitted
- 8 Mar 2019
- Last updated
- 28 Sep 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Paulussen KJ, Barnes TM, Askow AT, Salvador AF, McKenna CF, Scaroni SE, Fliflet A, Ulanov AV, Li Z, West DW, Bauer LL, Paluska SA, Dilger RN, Moore DR, Boppart MD, Burd NA. Underpinning the Food Matrix Regulation of Postexercise Myofibrillar Protein Synthesis by Comparing Salmon Ingestion With the Sum of Its Isolated Nutrients in Healthy Young Adults. J Nutr. 2023 May;153(5):1359-1372. doi: 10.1016/j.tjnut.2023.02.037. Epub 2023 Mar 2.
PubMed 36870539
Study at a glance
From the registry record, last updated by the sponsor on 28 Sep 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Food First Approach to Stimulate Muscle Protein Synthesis in Healthy Adults
- ClinicalTrials.gov ID
- NCT03870165
- Acronym / sponsor ID
- Salmon / 19293
- Conditions
- Hypertrophy
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 10 participants (actual)
- Lead sponsor
- University of Illinois at Urbana-ChampaignUniversity, hospital or other
- Study start
- 1 Mar 2019 (actual)
- Primary completion
- 22 Nov 2019 (actual)
- Study completion
- 22 Nov 2019 (actual)
- First posted
- 11 Mar 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In a crossover design 10 young healthy adults (20-35 y) will receive stable isotope tracer infusions and perform a single bout of resistance exercise. Immediately after exercise participants will ingest either 3.5 oz of Salmon fillet or its constituent macronutrients as isolated amino acids and fat. Repeated blood and breath samples as well as muscle biopsies will be collected to determine whole body amino acid kinetics, muscle amino acid transporters, anabolic signalling and myofibrillar protein synthesis rates during the trials
Detailed description
On both infusion trials, participants will report to the laboratory at 0700 h after an overnight fast. Upon arrival to the lab, the participant will fill out a questionnaire and a baseline breath sample will be collected to determine 13CO2 enrichment by isotope ratio mass spectrometry. A Teflon catheter will be inserted into the antecubital vein for a baseline blood sample (t=-210) and then participants will receive priming doses of NaH13CO2 (2.35 µmol·kg-1), L-[1-13C]leucine (7.6 µmol·kg-1), and L-[ring-2H5]phenylalanine (2.0 µmol·kg-1). Subsequently, a continuous intravenous solution of L-[1-13C]leucine (0.10 µmol·kg-1·min-1) and L-[ring-2H5]phenylalanine (0.05 µmol·kg-1·min-1) will be initiated (t=-210) and maintained over the infusion trials. A second Teflon catheter will be inserted into a heated dorsal vein for repeated arterialized blood sampling and remained patent by a 0.9% saline drip. Breath samples and arterialized blood samples will be collected every 30 to 60 minutes during the postabsorptive and postprandial states. In the post-absorptive state of infusion trial 1, muscle biopsies will be collected at t=-150 and -30 min of infusion to determine basal-state myofibrillar protein synthesis rates, relative skeletal muscle amino acid transporter content, and anabolic-related signaling. In the subsequent cross-over trial only 1 muscle biopsy will be collected at t=-30 for Western blot analysis and postabsorptive myofibrillar protein-bound tracer enrichment. After collection of the resting muscle biopsy at t=-30 for both trials, the participants will perform resistance exercise that consists of 4 sets of 10-12 repetitions or to muscular failure at 65-70% of 1-RM for both leg press and leg extension exercise.
Immediately after the completion of the exercise bout, participants will ingest either 3.5 oz of Salmon fillet or a matched isolated amino acid and fat mixture (t=0). Completion of the meal will mark the start of the postprandial stage and additional muscle biopsies will be collected at t=120 and t=300.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Salmon | Active comparator | Behavioral: Resistance exercise, Other: SalmonAfter resistance exercise, participants will ingest 3.5 oz of salmon fillet (21g protein, 24g fat) cooked sous-vide. |
| Isolated mixture | Experimental | Behavioral: Resistance exercise, Dietary Supplement: Isolated amino acids and fatty acidsAfter resistance exercise, participants will ingest an isolated amino acid and fatty acid mixture matched to the amino acid and fatty acid content of 3.5 oz salmon fillet. |
Who may qualify
- Ages
- 20 to 35 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Age 20-35 years
- Recreationally-active adults: ≥ 30 min of physical activity at moderate intensity ≥ 3 times per week
- English fluency
Key exclusion criteria (20 listed)
- Smoking
- Known allergies to fish consumption
- Vegans
- Diagnosed GI tract diseases
- Arthritic conditions
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Resistance exerciseParticipants will perform leg press and leg extension immediately prior to ingestion of salmon or isolated mixture | Behavioural | Isolated mixture, Salmon |
| SalmonParticipants will ingest salmon immediately after resistance exercise | Other | Salmon |
| Isolated amino acids and fatty acidsParticipants will ingest a mixture of isolated amino acids and fatty acids immediately after resistance exercise | Dietary supplement | Isolated mixture |
Primary outcome
Fractional synthetic rate of myofibrillar proteins
Time frame: Postabsorptive for 3 hours, postprandial for 5 hours.
Myofibrillar protein synthesis rates will be assessed during the postabsorptive period for 3 hr and during the 5 hr after the ingestion of the experimental interventions. This will allow us to assess the change from the postabsorptive to the postprandial period.
2 secondary outcomes
Phosphorylation of muscle anabolic signaling
Time frame: Baseline and at 2 and 5 hours after protein ingestion
Exogenous rate of leucine appearance
Time frame: 5 hour postprandial phase
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Sep 2020.
- Derived from this study: PubMed 36870539Paulussen KJ, Barnes TM, Askow AT, Salvador AF, McKenna CF, Scaroni SE, Fliflet A, Ulanov AV, Li Z, West DW, Bauer LL, Paluska SA, Dilger RN, Moore DR, Boppart MD, Burd NA. Underpinning the Food Matrix Regulation of Postexercise Myofibrillar Protein Synthesis by Comparing Salmon Ingestion With the Sum of Its Isolated Nutrients in Healthy Young Adults. J Nutr. 2023 May;153(5):1359-1372. doi: 10.1016/j.tjnut.2023.02.037. Epub 2023 Mar 2.
- Individual participant dataSharing planned: No
Related trials for Hypertrophy
Not yet recruiting
Human Experimental Models of Pain (HEMP)
Acute Pain
Not yet recruiting
Pilot Study Evaluating Catheter Directed Thrombolysis Device in Acute Intermediate Risk Pulmonary Embolism
Pulmonary Embolism (PE), Pulmonary Embolism With Right Ventricle Enlargement
Not yet recruiting
NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Multi-Center Prospective Study Using Improvised Off-Label Devices
Hypertrophic Cardiomyopathy, Left Ventricular Outflow Obstruction
Active, not recruitingEarly Phase 1
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
B-ALL, DLBCL
RecruitingObservational study
Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics
Familial Mediterranean Fever (FMF), Autoinflammation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Nicholas A Burd, PhD principal investigator
University of Illinois at Urbana-Champaign
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Resistance exercise, Salmon and Isolated amino acids and fatty acids in people with Hypertrophy, run by University of Illinois at Urbana-Champaign at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Sep 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Fractional synthetic rate of myofibrillar proteins (time frame: Postabsorptive for 3 hours, postprandial for 5 hours.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03870165, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Sep 2020.